Literature DB >> 16189111

Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Berta Bosch1, Julià Blanco, Eduardo Pauls, Imma Clotet-Codina, Mercedes Armand-Ugón, Boyan Grigorov, Delphine Muriaux, Bonaventura Clotet, Jean-Luc Darlix, José A Esté.   

Abstract

We have previously shown (J. Blanco et al., J. Biol. Chem. 279:51305-51314, 2004) that the contact between HIV producing cells and primary CD4(+) T cells may induce the uptake of human immunodeficiency virus (HIV) particles by target cells in the absence of HIV envelope-mediated membrane fusion or productive HIV replication. HIV uptake by CD4(+) T cells was dependent on cellular contacts mediated by the binding of gp120 to CD4 but was independent of the expression of the appropriate HIV coreceptor, CCR5 or CXCR4. Here, we have characterized the effect of agents blocking gp120 binding to CD4 on cell-to-cell HIV transmission. A recombinant CD4-based protein (CD4-immunoglobulin G2 [IgG2]), that is currently being evaluated in clinical trials, completely inhibited the uptake of HIV particles by CD4(+) T cells from persistently infected cells expressing R5, X4, or X4/T-20-resistant HIV-1 envelope glycoproteins. Consequently, both the release of viral particles from endocytic vesicles and the infection of reporter U87-CD4 cells were also prevented. The polyanionic anti-HIV agent dextran sulfate failed to prevent the intracellular uptake of virions by CD4(+) T cells. Indeed, it increased HIV uptake in a dose-dependent manner, suggesting functional differences between the specific gp120-targeting CD4-IgG2 agent and nonspecific HIV binding inhibitors. Thus, the inhibition of the specific interaction between gp120 and CD4 protein could be an effective strategy to inhibit HIV binding to CD4(+) T cells, and the mechanism by which CD4(+) T cells lacking the appropriate coreceptor may be converted in HIV carriers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189111      PMCID: PMC1251523          DOI: 10.1128/AAC.49.10.4296-4304.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Authors:  P Zhu; W C Olson; K H Roux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro.

Authors:  J Blanco; J Barretina; C Cabrera; A Gutiérrez; B Clotet; J A Esté
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

3.  Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells.

Authors:  Julià Blanco; Jordi Barretina; Arantxa Gutiérrez; Mercedes Armand-Ugón; Cecilia Cabrera; Bonaventura Clotet; José A Esté
Journal:  AIDS Res Hum Retroviruses       Date:  2002-01-01       Impact factor: 2.205

4.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo.

Authors:  A Llano; J Barretina; J Blanco; A Gutiérrez; B Clotet; J A Esté
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

6.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

Authors:  J M Jacobson; I Lowy; C V Fletcher; T J O'Neill; D N Tran; T J Ketas; A Trkola; M E Klotman; P J Maddon; W C Olson; R J Israel
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

7.  Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.

Authors:  Julià Blanco; Imma Clotet-Codina; Berta Bosch; Mercedes Armand-Ugón; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.

Authors:  A Llano; J Barretina; A Gutiérrez; J Blanco; C Cabrera; B Clotet; J A Esté
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.

Authors:  Jordi Barretina; Julià Blanco; Mercedes Armand-Ugón; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Journal:  Antivir Ther       Date:  2003-04

10.  Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression.

Authors:  Anuska Llano; Jordi Barretina; Arantxa Gutiérrez; Bonaventura Clotet; José A Esté
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  12 in total

1.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Induction of interleukins IL-6 and IL-8 by siRNA.

Authors:  E Pauls; J Senserrich; M Bofill; B Clotet; J A Esté
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

3.  Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells.

Authors:  Marc Permanyer; Ester Ballana; Roger Badia; Eduardo Pauls; Bonaventura Clotet; José A Esté
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

4.  HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis.

Authors:  Nikolas Herold; Maria Anders-Ößwein; Bärbel Glass; Manon Eckhardt; Barbara Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

5.  Antiretroviral agents effectively block HIV replication after cell-to-cell transfer.

Authors:  Marc Permanyer; Ester Ballana; Alba Ruiz; Roger Badia; Eva Riveira-Munoz; Encarna Gonzalo; Bonaventura Clotet; José A Esté
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

6.  Inefficient human immunodeficiency virus replication in mobile lymphocytes.

Authors:  Marion Sourisseau; Nathalie Sol-Foulon; Françoise Porrot; Fabien Blanchet; Olivier Schwartz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.

Authors:  Nuria Izquierdo-Useros; Julià Blanco; Itziar Erkizia; Maria Teresa Fernández-Figueras; Francesc E Borràs; Mar Naranjo-Gómez; Margarita Bofill; Lidia Ruiz; Bonaventura Clotet; Javier Martinez-Picado
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition.

Authors:  Nicola Martin; Sonja Welsch; Clare Jolly; John A G Briggs; David Vaux; Quentin J Sattentau
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Authors:  Marek Malecki; Bianka Saetre
Journal:  Mol Cell Ther       Date:  2018-06-21

10.  HIV Universal Vaccine.

Authors:  Marek Malecki; Bianka Saetre
Journal:  Mol Cell Ther       Date:  2018-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.